BERLIN (Reuters) - German biotech firm CureVac has started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and ...

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...

TÜBINGEN, Germany / BOSTON, USA – August 15, 2025 – CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA ...

The merger process reached its formal conclusion on January 6, 2026, with Mainz-based BioNTech SE becoming the sole owner. The operational entity, CureVac Merger B.V., has replaced the original ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Friday that it will receive an upfront settlement of $370 million from CureVac N.V. following the mRNA patent settlement reached between ...

CureVac says vaccine can be kept in fridge for 3 mths Behind in development but logistics could give it an edge Rival BioNTec's vaccine only lasts 5 days in fridge BERLIN, Nov 12 (Reuters) - German ...

TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative ...

Curevac N.V. ( (CVAC)) has released its Q2 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...